Opinion|Videos|December 18, 2024
From Collection to Infusion: Comprehensive CAR T Treatment and Management Strategies From CAR T Specialists
Panelists discuss how patients and medical teams navigate the complex CAR T therapy journey, from initial referral through cell collection, manufacturing, and infusion, while highlighting crucial monitoring strategies for managing adverse effects such as cytokine release syndrome and neurotoxicity.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Could you describe your experience during the referral, CAR T cell collection, manufacturing, and infusion process? How did your care team support you throughout your journey? What resources and communities did you find most supportive as you navigated this process and recovery?
- What is your approach to monitoring and managing patients throughout CAR T collection, manufacturing, and infusion? How do you monitor and manage key CAR T–specific adverse effects such as cytokine release syndrome or neurotoxicity? Do you have any key prophylactic strategies or best practices for optimal patient outcomes and safety?
Advertisement
Related to this article
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.
Full results from the phase 3 CERVINO trial assessing etentamig in relapsed/refractory multiple myeloma will be shared at the 23rd IMS Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
2
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
3
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
4
PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data
5